A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

WEHI researchers have solved a decades-long mystery by determining the structure of human PINK1, a key protein linked to ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

A groundbreaking treatment for prostate cancer now available in Virginia aims to improve patient outcomes while minimizing side effects associated with traditional surgeries and radiation therapies.

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Interleukin 15 expression in asthmatic airways negatively correlated with lung function, a finding that improves ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...